KAPA
Kairos Pharma, Ltd.
NYSE MKT: KAPA · HEALTHCARE · BIOTECHNOLOGY
$0.55
-6.44% today
Updated 2026-04-29
Market cap
$12.83M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.30
Dividend yield
—
52W range
$0 – $2
Volume
0.6M
Kairos Pharma, Ltd. (KAPA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $-38535.00 | $-412000.00 | $-353000.00 | $81000.00 | $-3.96M | $-3.44M |
| Capital expenditures | $5.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | $0.00 | $98000.00 | $160000.00 | $160000.00 | $160000.00 | — |
| Stock-based comp | $800000.00 | $300000.00 | $0.00 | $913000.00 | $218000.00 | — |
| Free cash flow | $-38540.00 | $-412000.00 | $-353000.00 | $81000.00 | $-3.96M | $-3.44M |
| Investing cash flow | — | $-109000.00 | — | — | — | — |
| Financing cash flow | $37000.00 | $580000.00 | $717000.00 | $-425000.00 | $5.13M | — |
| Dividends paid | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — |